文献速递肝病消化道肿瘤与早癌

美国未接受治疗的慢性乙型肝炎患者接受富马酸替诺福韦二吡呋酯与恩替卡韦的肝细胞癌风险比较

Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-08

本研究基于美国商业保险理赔数据库,比较未接受治疗的慢性乙型肝炎患者使用富马酸替诺福韦二吡呋酯(TDF)与恩替卡韦(ETV)的肝细胞癌(HCC)发生风险。倾向评分加权多变量分析显示,TDF与ETV相比HCC的子分布风险比为0.58(95%CI 0.38-0.89)。

要点

  • 在未接受治疗的慢性乙型肝炎患者中,TDF与ETV相比HCC风险显著降低,子分布HR为0.58(95%CI 0.38-0.89)。
  • TDF组粗发病率为0.30/100人年,ETV组为0.62/100人年,随访期间共90例发生HCC。
  • 在≥40岁患者及男性和女性中分别分析,结果相似。

核心结论

  • 在美国商业保险覆盖的未接受治疗的慢性乙型肝炎患者中,TDF治疗与ETV相比HCC风险显著降低。

研究设计与样本

  • 基于大型商业保险理赔行政数据库的队列研究,纳入166,933例成人慢性乙型肝炎患者,其中3934例启动ETV,6127例启动TDF。
  • 采用融入治疗倾向评分的Fine-Gray风险回归模型估计TDF与ETV相比的HCC发生风险。
  • 调整变量包括人口学特征、合并用药和基线合并症,竞争事件包括肝移植和换药。

主要发现

  • 倾向评分加权后TDF组与ETV组匹配良好。
  • 随访期间共90例发生HCC,其中ETV组50例,TDF组40例。
  • ETV组粗发病率为0.62/100人年,TDF组为0.30/100人年。
  • 倾向评分加权多变量分析中,TDF与ETV相比HCC的子分布风险比为0.58(95%CI 0.38-0.89)。
  • 在≥40岁患者以及男性和女性中分别分析,结果相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the first-line treatment agents for chronic hepatitis B virus (HBV). Recently, whether the degree to which the risk of hepatocellular carcinoma (HCC) may be reduced by ETV vs TDF has been debated. We compared the incidence of HCC among treatment-naïve patients receiving TDF vs ETV in the United States. METHODS: From a large administrative medical claims database of commercially insured patients, we identified 166,933 adults with a diagnosis of chronic hepatitis B and a minimum of 12 months of prior enrolment, of whom 3934 and 6127 initiated ETV and TDF respectively. Fine-Gray hazard regression models incorporating treatment propensity scores (PS) were used to estimate the risk of HCC incidence associated with TDF vs ETV; variables considered for adjustment included demographic characteristics, concomitant medication use and baseline comorbidities, as well as competing events including liver transplantation and medication changes. RESULTS: After PS weighting, the TDF and ETV groups were well-matched. During the follow-up, 90 patients developed HCC, including 50 receiving ETV and 40 receiving TDF, giving rise to crude incidence rates of 0.62 per 100 person-years (PY) and 0.30 per 100 PY respectively. In PS-weighted, multivariable analysis, TDF was associated with a subdistribution hazard ratio for HCC of 0.58 (95% confidence interval [CI]: 0.38-0.89) compared to ETV. Results were similar when patients ≥40 years and men and women were analysed separately. CONCLUSION: Among commercially insured, treatment-naïve patients with chronic hepatitis B in the United States, treatment with TDF was associated with significantly lower risk of HCC than ETV.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim WR, Telep LE, Jump B, et al. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther. 2022. PMID: 35137422. doi:10.1111/apt.16786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。